Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tralesinidase Alfa · AX 250, BMN-250

Recombinant protein · Protein replacement · developed by Spruce Biosciences

Phase 3 Most advanced trial
SPRB Developer
1 Registered trials

What is Tralesinidase Alfa?

Tralesinidase alfa is a sterile solution given by intracerebroventricular (ICV) infusion. It is studied in mucopolysaccharidosis III (MPS IIIB).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AX 250, BMN-250
Drug type
Recombinant protein
Mechanism
Protein replacement
Therapy area
Metabolic
Developer
Spruce Biosciences (SPRB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
AA60A4ST8X

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07579910 Phase 3 MPS IIIB Not yet recruiting SPRB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MPS IIIB

More from Spruce Biosciences

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SPRB page.

Follow SPRB, the company behind Tralesinidase Alfa

See SPRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SPRB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.